Why does the loss occur at all?
Dispensing at a loss often feels like a purchasing failure, as though a better buyer would have avoided it. The structure says otherwise. Understand the structure, and the experience turns from a source of frustration into a manageable operational variable.
National community pharmacy funding in England has two elements. Remuneration is the fees and allowances paid for services performed. Retained margin is the difference between what a pharmacy pays for a medicine and what it is reimbursed — a difference pharmacies are permitted to keep as part of the agreed funding. For 2026/27 the core contractual framework provides £3.636 billion. Of that, £1.1 billion is intended for delivery as retained buying margin, a figure increased by £200 million as part of the settlement.
The consequence: a material portion of the sector's income is not paid but earned, through purchasing medicines below the reimbursement price. The Department delivers the margin target principally by adjusting reimbursement prices within Category M of the Drug Tariff. It sets them above the prices notified by manufacturers, so the difference accrues to contractors.
That mechanism works while the market behaves as the model assumes. Where a product's actual market price rises above its Tariff price — through shortage, manufacturer withdrawal, raw material cost or exchange rate movement — the arithmetic inverts. Every item dispensed produces a loss rather than a margin. The pharmacy has not purchased badly. The reimbursement price has been overtaken by the market it was set against.
How is reimbursement set?
Part VIII of the Drug Tariff sets reimbursement prices for generic medicines. Its categories operate differently, and the differences determine how quickly each responds to market movement.
| Category | What it covers | How the price behaves |
|---|---|---|
| Part VIIIA Category A | Products readily available, priced from a basket of supplier list prices | Moves with the sources it is drawn from, and may lag a rapid market change |
| Part VIIIA Category C | Products not readily available as generics, priced from a named source | Follows the nominated source rather than the wider market |
| Part VIIIA Category M | Products where the price is set to deliver the margin target | Adjusted periodically by the Department, deliberately above notified manufacturer prices |
| Parts VIIIB and VIIID | Specials and unlicensed imports, and certain other listed products | Concessions may also be requested here where sourcing above Tariff occurs |
Two features of that arrangement produce the recurring difficulty. Category M prices are set to achieve a national margin figure, not to track any individual product's market. An individual line can therefore be priced below its own market while the aggregate remains on target. And every category is set periodically while supply markets move daily, so a gap opens whenever a market moves faster than the review cycle.
A further consequence deserves noting, because it affects pharmacies unequally. Margin is delivered through prices some pharmacies capture better than others, depending on purchasing arrangements, volumes and product mix. So the funding is distributed unevenly across the sector. That is a recognised limitation of the mechanism, not a criticism of any particular pharmacy's buying.
What is a concession, and what is it not?
Where pharmacies cannot obtain a Part VIII product at or below its Tariff price, the Department of Health and Social Care may grant a price concession at the request of Community Pharmacy England. The concession raises the reimbursement price for that month. Contractors dispensing the affected product are reimbursed at the revised price automatically; no additional endorsement is required.
Three characteristics are worth stating precisely, because each is regularly misunderstood.
A concession is monthly. It applies for the month in which it is granted, not until withdrawn. A product conceded in one month reverts to its Tariff price in the next unless conceded again. Prices agreed for concessions requested late within a month roll over into the following month. Rolled-over prices may be adjusted upward where reports indicate suppliers' prices have risen further, and a review is available at any point during the month.
A concession is a reimbursement price rather than a reimbursement of loss. It sets what will be paid for items dispensed within that month. It does not compensate for the difference between what was paid for stock and what was received before the concession existed. Where purchasing and dispensing fall either side of a concession's timing, the shortfall is genuine.
A concession is applied for rather than triggered. No system detects that a market has moved. Community Pharmacy England applies on the basis of evidence submitted by contractors, and the Department decides. That dependency is the subject of the section below. It is the one element of the whole mechanism a pharmacy owner directly controls.
How does the monthly cycle operate?
Concessions are not published as a single monthly list. They are confirmed in tranches as applications are determined — a rhythm worth anticipating rather than reacting to.
July 2026 illustrates the pattern. An initial list was confirmed mid-month, with further lists following on subsequent dates. By the confirmation of 22 July, the total granted for the month had reached 183, with applications for additional products still outstanding. June 2026 concluded at 254 concessions granted. Community Pharmacy England publishes a dashboard tracking the monthly totals over time and by Drug Tariff category — the right source for anyone assessing whether a given month is unusual.
The operational consequence of tranching is a timing gap that affects every pharmacy the same way. Stock is purchased throughout the month, while concessions for that month may not be confirmed until its final week. A pharmacy therefore purchases in uncertainty and is reimbursed in retrospect. The interval between the two is where the discomfort sits. Nothing within the pharmacy's control removes that gap, though the purchasing habits described below reduce its cost.
Why does reporting decide the outcome?
No mechanism detects that a product has become unobtainable at Tariff price. Community Pharmacy England learns of it because dispensing contractors report what they paid and to whom, and applications to the Department are built from that evidence. The reporting route asks for the product, the supplier and the price paid — precisely the information sitting in a purchase invoice and nowhere else. So a pharmacy absorbing a loss silently has not merely accepted a cost. It has withheld the evidence the correction depends on, for itself and for every other pharmacy dispensing the same product. Reporting takes minutes. It feeds a system that reimburses automatically once the concession is granted. And it is the only part of this mechanism an individual owner influences directly. Treat it as a standing operational task, not an occasional grievance.
Two practical points improve the quality of what is submitted. Report with the invoice rather than from recollection: the application requires supplier and price, and an approximate figure weakens the evidence. And report promptly. A concession requested late in a month rolls into the next, while one requested early may be determined within the month the loss is being incurred.
What do concessions not fix?
The mechanism is a correction, not a solution. Anyone planning around it should understand four limitations.
The timing gap. Purchases precede concessions, and the interval is not compensated.
The threshold effect. A concession is granted where the evidence supports it. Losses on products with limited dispensing volume, or where reporting is thin, may persist uncorrected simply because the evidence never accumulated.
The distribution question. Margin is delivered through purchasing, and purchasing capability varies with scale and arrangements. So the funding does not reach every pharmacy equally, even when the national total is delivered.
The structural point. Concessions correct the symptom of a funding model that delivers a substantial proportion of income through the difference between two prices — one set administratively, the other by a market. The volume of concessions granted is therefore a measure of how frequently that model requires correction. That is why the sector's representative body publishes the trend, not merely the monthly list.
What is the operational response?
Four habits reduce the cost of the mechanism without pretending to remove it.
Purchase with the cycle in mind. Where a product is known to be under pressure, buying to need rather than to stock reduces exposure to the interval between purchase and concession. Shortage conditions frequently make the opposite necessary, though — and clinical continuity outranks margin in that judgement.
Reconcile rather than assume. Check reimbursement against expectation for the products where the amounts are material. Payment and pricing accuracy is itself a recognised issue, and a concession granted is not the same as a concession correctly applied to a particular month's dispensing.
Report as routine. A standing weekly task, assigned to a named person, converts reporting from something that happens when someone is sufficiently annoyed into something that happens whenever an invoice exceeds Tariff.
Watch the announcements deliberately. Concessions arrive in tranches, so a pharmacy checking once a month at the wrong moment sees an incomplete picture. The dashboard and update notices are more useful read on a schedule than encountered incidentally.
What is the 2026/27 position?
The concessions mechanism sits within a funding settlement that improved materially for 2026/27 while leaving the underlying structure intact. Core contractual framework funding rose by 10.3 per cent to £3.636 billion — the highest uplift across primary care for that year. The retained medicine margin increased by £200 million to £1.1 billion. The Government also agreed to write off historic net margin over-delivery earned to the end of March 2026, which Community Pharmacy England said saved pharmacy owners up to £239 million in recovery. The Single Activity Fee increased. Independent Prescribing within Pharmacy First and the Pharmacy Contraception Service were scheduled for introduction during the year.
Two observations follow for an owner reading this alongside their own accounts. The settlement was accepted on the condition of a shared programme of reform, not as a resolution; the sector's representative body was explicit that the uplift addressed the position without altering the model. And the margin element, though increased, remains an amount to be earned through purchasing rather than received. So the concessions mechanism, and the reporting it depends on, matters more rather than less as the figure rises.
For context on the volumes involved: the Department recorded that community pharmacies dispensed around one billion prescription items between April 2025 and January 2026. The same ten months brought over 2.75 million Pharmacy First clinical pathways consultations, nearly one million contraception service consultations and three million hypertension case-finding consultations.
A note on the devolved nations
The mechanism described here operates in England, where Community Pharmacy England negotiates with the Department of Health and Social Care and concessions apply to the English Drug Tariff. Scotland, Wales and Northern Ireland run their own reimbursement arrangements, with their own routes for products that cannot be obtained at reimbursement price. Terminology, timing and evidence requirements differ accordingly. Operators working across borders should treat the arrangements as separate rather than analogous, and consult the relevant national body rather than reasoning from the English position.
Key takeaways
- Dispensing at a loss is structural, not a purchasing failure. A substantial portion of English community pharmacy income is delivered as retained buying margin — £1.1 billion for 2026/27, within a £3.636 billion framework.
- Category M prices are set to deliver a national margin target, not to track individual products. Every Tariff category is reviewed periodically while markets move daily. That is where the gap originates.
- A concession raises the reimbursement price for the month it is granted, requires no additional endorsement, and applies automatically. It rolls over where agreed late and stays open to upward review.
- Concessions arrive in tranches rather than as one list: 254 granted for June 2026, and 183 for July 2026 as at 22 July. The trend is published as a dashboard by Drug Tariff category.
- The mechanism is evidence-led. Concessions are applied for using supplier and price data only dispensing contractors hold, so absorbing a loss silently withholds the evidence the correction depends on.
- Concessions do not compensate for the timing gap, do not reach products where evidence never accumulates, and do not resolve the uneven distribution that delivering funding through purchasing produces.
- The operational response: purchase with the cycle in mind, reconcile reimbursement rather than assuming it, report as a standing weekly task, and read the announcements on a schedule.
Sources and further reading
FAQs
Margin earned, not assumed.
Reporting above-Tariff purchases requires knowing which lines were bought above Tariff — a data question before it is an administrative one. Dataforge PMR holds dispensing and purchase records in one place, and the reconciliation habit this article describes runs on exactly that. Where the loss is visible only at the quarter end, the records are the constraint, not the market.
See Dataforge PMR